March 01, 2017
FOR IMMEDIATE RELEASE February 28, 2017
Media Contact:
Julie Calzone
(337) 235-2924
Company Contacts:
Thomas J. Concannon, CEO
(908) 625-7811
G. Darcy Klug, Chairman and CFO
(337) 269-5933
REDHAWK COMMENCES SALE OF BRANDED GENERICS TO CLINICAL COMMISSIONING GROUPS
Youngsville, Louisiana – RedHawk Holdings Corp. (OTCQB: IDNG) (“RedHawk”
or the “Company”) announced today that EcoGen Europe Limited (“EcoGen”)
has commenced the process of selling its branded generic pharmaceutical
drugs to a Clinical Commissioning Group (“CCG”). Initial deliveries of
EcoGen’s branded generics to this first CCG are expected to commence
during March 2017. There are currently 212 CCG’s and the Company
believes more CCG’s will begin taking delivery of EcoGen’s branded
generics in the coming months.
CCG’s
are organizations set up in the United Kingdom by the National Health
Service (“NHS”) to organize the delivery of NHS services throughout
England. They are clinically led groups that include all general
practitioners in their geographic area. The aim of this structure is to
give general practitioners and other clinicians the power to influence
commissioning decisions for their patients. CCG’s are overseen by the
NHS and operate by commissioning or buying healthcare services including
pharmaceuticals, elective hospital care, rehabilitation care, urgent
and emergency care and most community health services. CCG’s work with
patients and healthcare professionals in partnership with local
communities and authorities.
# # #
About RedHawk Holdings Corp.
RedHawk Holdings Corp., formerly Independence Energy Corp.,
is a diversified holding company which, through its subsidiaries, is
engaged in sales and distribution of medical devices, sales of branded
generic pharmaceutical drugs, commercial real estate investment and
leasing, sales of point of entry full-body security systems, and
specialized financial services. Through its medical products business
unit, the Company sells WoundClot Surgical - Advanced Bleeding Control,
the Sharps and Needle Destruction Device (SANDD™), the Carotid Artery
Digital Non-Contact Thermometer and Zonis®. Its real estate leasing
revenues are generated from various commercial properties under
long-term lease. Additionally, RedHawk’s real estate investment unit
holds limited liability company interest in various commercial
restoration projects in Hawaii. The Company’s financial service revenue
is from brokerage services earned in connection with debt placement
services. RedHawk Energy holds the exclusive U.S. manufacturing and
distribution rights for the Centri Controlled Entry System, a unique,
closed cabinet, nominal dose transmission full body x-ray scanner.
Cautionary Statement Regarding Forward Looking Statements
This release may contain forward-looking statements.
Forward-looking statements are all statements other than statements of
historical fact. Statements contained in this release that are not
historical facts may be deemed to be forward-looking statements. The
words “anticipate,” “may,” “can,” “plans,” “believes,” “estimates,”
“expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,”
“to be,” “potential” and any similar expressions are intended to
identify those assertions as forward-looking statements.
Investors are cautioned that forward-looking statements are
inherently uncertain. Actual performance and results may differ
materially from that projected or suggested herein due to certain risks
and uncertainties. In evaluating forward-looking statements, you should
consider the various factors which may cause actual results to differ
materially from any forward-looking statements including those listed in
the “Risk Factors” section of our latest 10-K report. Further, the
Company may make changes to its business plans that could or will affect
its results. Investors are cautioned that the Company will undertake no
obligation to update any forward-looking statements.
No comments:
Post a Comment